Related references
Note: Only part of the references are listed.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers
Mohit Mathur et al.
KIDNEY INTERNATIONAL REPORTS (2022)
A review of the AURORA and BLISS trials: will it revolutionize the treatment of lupus nephritis?
Sabaa Asif et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2022)
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma
Yu Rebecca Miao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2022)
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Dennis S. W. Lee et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Function, occurrence and inhibition of different forms of BAFF
Mahya Eslami et al.
CURRENT OPINION IN IMMUNOLOGY (2021)
Telitacicept: First Approval
Sohita Dhillon
DRUGS (2021)
Anifrolumab: First Approval
Emma D. Deeks
DRUGS (2021)
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease
Fan Shi et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2021)
Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections)
Cara D. Varley et al.
CURRENT RHEUMATOLOGY REPORTS (2021)
Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF
William Stohl et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains
Steven D. Levin et al.
FRONTIERS IN IMMUNOLOGY (2020)
Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders
Celine Kaegi et al.
FRONTIERS IN IMMUNOLOGY (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
Shereen Oon et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy
James R. Myette et al.
KIDNEY INTERNATIONAL (2019)
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib
Emily M. McWilliams et al.
BLOOD ADVANCES (2019)
Therapeutic effects of a novel BAFF blocker on arthritis
Bailing Zhou et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders
Jean Jacques Tudesq et al.
AUTOIMMUNITY REVIEWS (2018)
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases
Eileen Samy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2017)
A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells
Philipp Haselmayer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Romain Banchereau et al.
CELL (2016)
Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy
Ya-Ling Zhai et al.
MEDICINE (2016)
Bion-1301: A Novel Fully Blocking APRIL Antibody for the Treatment of Multiple Myeloma
John Dulos et al.
BLOOD (2016)
Stoichiometry of Heteromeric BAFF and APRIL Cytokines Dictates Their Receptor Binding and Signaling Properties
Sonia Schuepbach-Mallepell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Reactive Oxygen Species Deficiency Induces Autoimmunity with Type 1 Interferon Signature
Tiina Kelkka et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease
Helena Marco et al.
BMC MUSCULOSKELETAL DISORDERS (2014)
Belimumab for Systemic Lupus Erythematosus
Bevra Hannahs Hahn
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Selective APRIL Blockade Delays Systemic Lupus Erythematosus in Mouse
Bertrand Huard et al.
PLOS ONE (2012)
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
Ellen M. Ginzler et al.
ARTHRITIS RESEARCH & THERAPY (2012)
BAFF inhibition: A new class of drugs for the treatment of autoimmunity
Zheng Liu et al.
EXPERIMENTAL CELL RESEARCH (2011)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
Stacey R. Dillon et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Cytokine-producing B lymphocytes - key regulators of immunity
Frances E. Lund
CURRENT OPINION IN IMMUNOLOGY (2008)
Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL
Micah J. Benson et al.
JOURNAL OF IMMUNOLOGY (2008)
Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept
Michela Carbonatto et al.
TOXICOLOGICAL SCIENCES (2008)
Similarities and differences between selective and nonselective BAFF blockade in murine SLE
M Ramanujam et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Structures of APRIL-receptor complexes - Like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding
SG Hymowitz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Impaired IgA class switching in APRIL-deficient mice
E Castigli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases
V Roschke et al.
JOURNAL OF IMMUNOLOGY (2002)
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1
M Hezareh et al.
JOURNAL OF VIROLOGY (2001)
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS
JA Gross et al.
IMMUNITY (2001)
Share Paper
